Less than two weeks after Warren Buffett announced his retirement as CEO of Berkshire Hathaway, his successor made a statement that reverberated through boardrooms and trading desks alike. Greg Abel, the 62-year-old Canadian who will formally take the reins at year’s end, orchestrated a $26.3 billion acquisition of Haemonetics — a blood plasma technology company that most casual investors had never heard of. The deal wasn’t just large. It was a declaration.
The message to Wall Street, to Berkshire’s sprawling empire of subsidiaries, and to the legions of Buffett disciples watching nervously: the new boss intends to put Berkshire’s legendary cash pile to work. Aggressively.
A Cash Hoard Meets a New Appetite for Dealmaking
Berkshire Hathaway ended the first quarter of 2025 sitting on roughly $347 billion in cash and short-term Treasury bills — a figure that had become a source of both comfort and frustration for shareholders. Buffett himself acknowledged the stockpile’s enormity at the company’s annual meeting in Omaha on May 3, the same gathering where he stunned attendees by revealing his plan to step down. For years, the Oracle had preached patience, insisting he wouldn’t overpay simply to deploy capital. The cash kept growing.
Abel appears to share Buffett’s discipline but not his willingness to wait indefinitely. According to Yahoo Finance, the Haemonetics deal represents the largest Berkshire acquisition since the $37.2 billion purchase of Alleghany Corp. in 2022 — a transaction Buffett himself engineered. At $26.3 billion, the plasma technology acquisition ranks among the top ten deals in Berkshire’s history. And it came together with striking speed.
The timeline matters. Buffett’s retirement announcement landed on May 3. The Haemonetics deal was announced on May 15. Twelve days. That kind of velocity suggests Abel had been laying groundwork well before the succession became official — likely with Buffett’s knowledge and blessing, but under his own strategic direction.
Haemonetics, headquartered in Boston, specializes in blood management solutions and plasma collection technology. It’s not a flashy Silicon Valley play or a consumer brand with household recognition. It’s an industrial-medical company with sticky customer relationships, recurring revenue streams, and a dominant position in a niche but growing market. In other words, it’s exactly the kind of business Berkshire has always favored — except it operates in healthcare, a sector where Berkshire’s footprint has historically been modest.
That’s what makes this interesting.
Buffett largely avoided healthcare acquisitions during his tenure, despite occasional forays like the ill-fated joint venture with Amazon and JPMorgan Chase called Haven, which collapsed in 2021. The sector’s regulatory complexity, reimbursement uncertainty, and political sensitivity made it a minefield for a conglomerate built on predictable cash flows. Abel’s willingness to step into this territory signals either supreme confidence in Haemonetics’ specific economics or a broader philosophical shift in how Berkshire evaluates opportunity.
Probably both.
The plasma industry has been on a growth tear. Global demand for plasma-derived therapies — used to treat immune deficiencies, hemophilia, and other chronic conditions — has surged in recent years. Collection volumes need to expand significantly to meet projected demand through 2030 and beyond. Haemonetics supplies the equipment and software that plasma collection centers depend on, making it something close to a toll-booth operator in a high-growth corridor. The business model generates the kind of durable competitive advantage that Buffett always called a “moat.”
Abel is betting that moat is wide enough.
What This Tells Us About the Abel Doctrine
Industry analysts have been parsing the Haemonetics acquisition for clues about how Abel will run Berkshire differently from his predecessor. Several themes are emerging.
First, speed. Buffett was famously deliberate, sometimes spending years circling a target before making an offer — or walking away entirely. Abel’s rapid execution suggests a leader who, once convinced of a thesis, moves decisively. This could mean Berkshire becomes a more active acquirer under his watch, which would be welcome news for shareholders who’ve argued the company’s cash position had become a drag on returns.
Second, sector expansion. Berkshire’s portfolio is heavily weighted toward insurance (GEICO, Berkshire Hathaway Reinsurance), energy (Berkshire Hathaway Energy), railroads (BNSF), and a constellation of manufacturing and retail businesses. Healthcare has been conspicuously underrepresented. The Haemonetics deal could be the first step toward building a meaningful healthcare vertical within the conglomerate. Or it could be a one-off. But the willingness to go there at all represents a departure.
Third, valuation tolerance. Early reports suggest Berkshire paid a meaningful premium to Haemonetics’ pre-deal trading price. Buffett was legendarily cheap — he wanted bargains, and he was willing to let deals die rather than overpay by a dollar. Abel may be more willing to pay fair value for high-quality businesses, recognizing that in a market where private equity firms and sovereign wealth funds compete for every attractive target, extreme frugality can mean missing out entirely.
This doesn’t mean Abel is reckless. Far from it. His track record running Berkshire Hathaway Energy — where he turned a mid-sized utility into one of the largest energy companies in the United States — demonstrates operational rigor and capital allocation skill. He didn’t get the top job by being impulsive. But his definition of a good deal may have slightly different parameters than Buffett’s, calibrated for a world where asset prices are structurally higher and competition for quality businesses is fierce.
The market’s initial reaction was cautiously positive. Berkshire Class A shares held steady in the days following the announcement, suggesting investors weren’t spooked by the price tag or the sector choice. Haemonetics shareholders, predictably, cheered. The stock jumped on the news.
Not everyone is convinced. Some longtime Berkshire watchers have questioned whether a $26.3 billion healthcare acquisition is the best use of capital when Berkshire could be buying back its own shares or increasing its stakes in publicly traded companies like Apple, Bank of America, or Coca-Cola. Share buybacks, in particular, have been a favored tool in recent years — Berkshire repurchased more than $70 billion of its own stock between 2020 and 2024. But Buffett slowed buybacks considerably in his final quarters, suggesting he believed Berkshire’s stock was no longer undervalued enough to justify aggressive repurchases.
Abel may agree. And if Berkshire’s stock trades at or above intrinsic value, deploying cash into acquisitions that generate attractive returns becomes the logical alternative. The math isn’t complicated: $347 billion earning Treasury yields of roughly 4-5% produces solid income but doesn’t compound the way owning great businesses does. Every dollar sitting in T-bills is a dollar not earning the 15-20% returns on equity that Berkshire’s best subsidiaries generate.
So the pressure to deploy is real. It’s been real for years. Abel is simply the first Berkshire CEO in six decades who isn’t Warren Buffett — and who therefore doesn’t get a pass from shareholders for sitting on cash because, well, he’s Warren Buffett.
The Haemonetics deal also raises questions about Berkshire’s pipeline. Is this the beginning of an acquisition spree? Abel has reportedly told associates he’s evaluating multiple potential targets across several industries, though no additional deals are imminent. The company’s sheer financial firepower — even after the Haemonetics purchase, Berkshire will have north of $320 billion in cash — means it can pursue virtually any acquisition short of buying one of the mega-cap tech giants.
That’s an extraordinary position. No other company on Earth has that kind of dry powder combined with a AAA-equivalent balance sheet and zero need to access debt markets. Abel inherits what is essentially a permanent capital vehicle with no redemption pressure, no activist investors demanding immediate returns, and a shareholder base that has been conditioned over decades to think in terms of years and decades rather than quarters.
The question is whether he’ll use that advantage boldly enough.
The Shadow of Succession
Every CEO transition at an iconic company carries risk. When the departing leader is Warren Buffett — arguably the most celebrated investor in history — the risk is amplified exponentially. Abel knows this. He’s spoken publicly about his respect for Berkshire’s culture and his intention to preserve the decentralized management structure that gives subsidiary CEOs enormous autonomy. He’s pledged not to sell any of his Berkshire shares. He’s said all the right things.
But saying the right things and doing the right things under pressure are different. The Haemonetics acquisition is the first real test. It will be judged not on its announcement-day optics but on its five-year and ten-year returns — the Berkshire way.
Buffett, for his part, has expressed full confidence in Abel. At the annual meeting, he told shareholders that Abel was “ready” and that the transition would not alter Berkshire’s fundamental character. He’ll remain as chairman, providing counsel but not control. It’s an arrangement that mirrors how many founder-led companies handle succession — the patriarch stays close but lets the new generation lead.
Whether that dynamic works smoothly in practice remains to be seen. Buffett’s gravitational pull is immense. Every major decision Abel makes will inevitably be compared to what Buffett might have done. The Haemonetics deal will be dissected through that lens: Would Buffett have bought it? Would he have paid that price? Would he have moved that fast?
These are unanswerable questions, and Abel would be wise to stop trying to answer them. The most successful corporate successors — think Tim Cook at Apple, or Jamie Dimon’s eventual replacement at JPMorgan — are those who honor the institution’s values while bringing their own judgment and instincts to bear. Abel’s instincts led him to a $26.3 billion bet on blood plasma technology. It’s unconventional. It’s bold. And it’s entirely his own.
The Berkshire faithful will be watching every move from here. The cash pile is still enormous. The opportunities, presumably, are out there. And Greg Abel has made clear that he doesn’t intend to let $347 billion sit idle while the world waits for the next perfect pitch.
Buffett always said he liked to swing only at fat pitches. Abel, it seems, may have a slightly wider strike zone. For Berkshire shareholders, that could be exactly what’s needed — or it could be the beginning of a very different era. Twelve days in, the early returns are promising. But in Omaha, they measure returns in decades.
The clock just started.
WebProNews is an iEntry Publication